Skip to main content

Table 2 Synergy experiments with HMCLs

From: Targeting phosphoglycerate dehydrogenase in multiple myeloma

A

B

CBR5884

NCT-503

Cells

Proteosome inhibitor

IC50 of PI

Fold change in IC50

P value

Cells

Proteosome inhibitor

IC50 of PI

Fold change in IC50

P value

- CBR

 + CBR

- NCT

 + NCT

INA6

Carf

1.2

1.1

0.90

0.5074

INA6

Carf

1.2

1.2

0.98

0.8862

BTZ

14.6

16.5

1.13

0.0406

BTZ

15.4

8.6

0.56

 < 0.0001

KJON1

Carf

2.4

2.1

0.88

0.1246

KJON1

Carf

2.7

3.3

1.22

0.0186

BTZ

27.4

24.6

0.90

0.1895

BTZ

26.1

19.3

0.74

0.0001

IH1

Carf

5.2

4.1

0.79

0.0058

IH1

Carf

5.6

6.4

1.15

0.0408

BTZ

14.7

12.6

0.86

0.1743

BTZ

12.7

11.1

0.88

0.0258

OH2

Carf

2.5

2.2

0.90

0.3532

OH2

Carf

2.6

2.6

1.01

0.9351

BTZ

11.0

9.2

0.84

0.0472

BTZ

11.5

6.5

0.56

 < 0.0001

JJN3

Carf

3.7

2.1

0.58

 < 0.0001

JJN3

Carf

3.7

5.8

1.59

 < 0.0001

BTZ

17.4

11.4

0.66

 < 0.0001

BTZ

16.7

15.4

0.92

0.2634

RPMI8226

Carf

3.2

1.5

0.47

 < 0.0001

RPMI8226

Carf

3.0

3.4

1.14

0.2898

BTZ

17.6

11.6

0.66

 < 0.0001

BTZ

16.8

10.5

0.62

 < 0.0001

ANBL6

Carf

6.4

4.3

0.67

 < 0.0001

ANBL6

Carf

5.7

7.8

1.36

0.0003

BTZ

21.5

14.7

0.69

0.0008

BTZ

21.5

15.2

0.71

0.0143

U266

Carf

5.6

3.2

0.57

 < 0.0001

U266

Carf

6.7

7.3

1.10

0.458

BTZ

23.0

13.3

0.58

 < 0.0001

BTZ

23.4

12.6

0.54

 < 0.0001

  1. HMCLS were treated with 1/3 of their corresponding IC50 of either A) CBR5884 (CBR) or B) NCT-503 (NCT), in combination with either carfilzomib (Carf) or bortezomib (BTZ). The table summarizes the proteasome inhibitors’ (PI) IC50 values obtained from the graphs shown in Additional file 1: Fig. S1A, B and C
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us